Ty-Jour T1 - 单细胞RNA测序识别肉芽肿疾病中的巨噬细胞转录异质性JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003 - 2003794-2020 SP - 2003794 Au - Liao，Shu-yi Au - Atif，Shaikh M。Au - Mold，Kara Au - Konigsberg，Iain R. Au - Fu，Rui Au - Davidson，Elizabeth Au - Li，Li Au - Fontenot，Andrew P. Au - Maier，Lisa A. Au - Yang，Ivana V.Y1- 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/02/11/13993003.03794-2020.Abstract n2 - 酸症和慢性铍病（CBD）是具有重叠临床的肉芽肿疾病然而，特征是他们的临床课程。CBD可能具有缓慢的临床进展，并且很少在结节病有变量进展时解决，并且可以根据疾病的阶段解决[1]。这些共性和差异意味着抗原的差异，以及潜在的间隙和持久性。肺泡巨噬细胞在该过程中发挥着重要作用，驱动先天[2]和适应性免疫应答[3]。此外，巨噬细胞的亚群可能促进粒细胞炎症和肺损伤的分辨率[4]，结节病和CBD的关键方面。使用单细胞RNA测序（ScRNA-SEQ），我们探讨了渐进性（SARCP）和剩余（SARCR）结节病和CBD和结节病之间的常见和独特途径，重点关注巨噬细胞和巨噬细胞群（招募与居民）.Footnotesthis令人呼吸杂志最近出版的稿件已被接受。它在汇款和排版的抄本之前在此处发布于其已接受的表单。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lindner has nothing to disclose.Conflict of Interest: Dr. Liao has nothing to disclose.Conflict of Interest: Dr. Atif has nothing to disclose.Conflict of Interest: Dr. Mould has nothing to disclose.Conflict of Interest: Dr. Konigsberg has nothing to disclose.Conflict of Interest: Dr. Fu has nothing to disclose.Conflict of Interest: Dr. Davidson has nothing to disclose.Conflict of Interest: Dr. Li has nothing to disclose.Conflict of Interest: Dr. Fontenot reports grants from National Institutes of Health (NIH), during the conduct of the study.Conflict of Interest: Dr. Maier reports grants from National Institutes of Health, during the conduct of the study; grants from National Institutes of Health, grants from University of Cincinnati under a Mallinckrodt Foundation, grants from MNK14344100, grants from ATYR1923-C-002, outside the submitted work; and Dr. Maier is a member of the FSR Scientific Advisory Board. She does not receive any compensation for this activity.Conflict of Interest: Dr. Yang reports grants from NIH, during the conduct of the study and personal fees from Eleven P15, outside the submitted work. In addition, Dr. Yang has a patent Circulating Biomarkers of Preclinical Pulmonary Fibrosis pending. ER -